The Li-Fraumeni syndrome

被引:50
作者
Chompret, A [1 ]
机构
[1] Inst Gustave Roussy, Dept Med, F-94805 Villejuif, France
关键词
Li-Fraumeni syndrome; germline TP53 mutation; germ-line CHK2 mutation;
D O I
10.1016/S0300-9084(01)01361-X
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Li-Fraumeni syndrome (LFS) has been the most common terminology used for the syndrome. It is a rare familial dominantly inherited cancer syndrome characterized by a wide spectrum of neoplasms occurring in children and young adults. The canonical definition of LFS includes a proband diagnosed with sarcoma before 45 years of age, a first-degree relative with cancer before this same age and another first or second-degree relative in the lineage with any cancer before this age or sarcoma at any age. Multiple studies have reported p53 germline mutations in LFS families in various parts of the world. As in sporadic tumors, loss of heterozygosity leading to the inactivation of the wild-type allele by deletion or mutation is observed in US tumors. Cancer-risk in mutation carriers has been estimated to be 73% in males and nearly 100% in females, the difference almost entirely explained by breast cancer. The identification of germline p53 mutations in rare cancer-prone families has given rise to the medical, counseling, psychological and ethical problems, (C) 2002 Societe francaise de biochimie et biologie moleculaire / Editions scientifiques et medicales Elsevier SAS.
引用
收藏
页码:75 / 82
页数:8
相关论文
共 100 条
  • [1] Arrowsmith CH, 1996, ONCOGENE, V12, P1379
  • [2] Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome
    Bell, DW
    Varley, JM
    Szydlo, TE
    Kang, DH
    Wahrer, DCR
    Shannon, KE
    Lubratovich, M
    Verselis, SJ
    Isselbacher, KJ
    Fraumeni, JF
    Birch, JM
    Li, FP
    Garber, JE
    Haber, DA
    [J]. SCIENCE, 1999, 286 (5449) : 2528 - 2531
  • [3] p53 gene mutation:: software and database
    Béroud, C
    Soussi, T
    [J]. NUCLEIC ACIDS RESEARCH, 1998, 26 (01) : 200 - 204
  • [4] Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome
    Birch, JM
    Blair, V
    Kelsey, AM
    Evans, DG
    Harris, M
    Tricker, KJ
    Varley, JM
    [J]. ONCOGENE, 1998, 17 (09) : 1061 - 1068
  • [5] LINKAGE STUDIES IN A LI-FRAUMENI FAMILY WITH INCREASED EXPRESSION OF P53 PROTEIN BUT NO GERMLINE MUTATION IN P53
    BIRCH, JM
    HEIGHWAY, J
    TEARE, MD
    KELSEY, AM
    HARTLEY, AL
    TRICKER, KJ
    CROWTHER, D
    LANE, DP
    SANTIBANEZKOREF, MF
    [J]. BRITISH JOURNAL OF CANCER, 1994, 70 (06) : 1176 - 1181
  • [6] BIRCH JM, 1994, CANCER RES, V54, P1298
  • [7] Relative frequency and morphology of cancers in carriers of germline TP53 mutations
    Birch, JM
    Alston, RD
    McNally, RJQ
    Evans, DGR
    Kelsey, AM
    Harris, M
    Eden, OB
    Varley, JM
    [J]. ONCOGENE, 2001, 20 (34) : 4621 - 4628
  • [8] EXCESS RISK OF BREAST-CANCER IN THE MOTHERS OF CHILDREN WITH SOFT-TISSUE SARCOMAS
    BIRCH, JM
    HARTLEY, AL
    MARSDEN, HB
    HARRIS, M
    SWINDELL, R
    [J]. BRITISH JOURNAL OF CANCER, 1984, 49 (03) : 325 - 331
  • [9] BIRCH JM, 1990, CANCER-AM CANCER SOC, V66, P2239, DOI 10.1002/1097-0142(19901115)66:10<2239::AID-CNCR2820661034>3.0.CO
  • [10] 2-Q